

Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer’s disease [Corrigendum]

Hager K, Baseman AS, Nye JS, Brashear HR, Han J, Sano M, Davis B, Richards HM. *Neuropsychiatr Dis Trea*. 2014;10:391–401.

“– Gal at stable dose (at least 18 mg/day) as achieved on day 84^c” should be “– Gal at stable dose (at least 16 mg/day) as achieved on day 84^c”. The correct figure is shown below.

On page 393, Figure 1, “Maintenance period (month 6 to 24)” should be “Maintenance period (month 4 to 24)”;

Pretreatment phase (day –28 to –1)

Baseline (day 0)

Treatment phase


Titration period (day 1 to 84)

- Gal 8 mg/day: day 1 to day 28
- Gal 16 mg/day: day 29 to day 56
- Gal up to 24 mg/day: day 57 to day 84^a
- Matching placebo

Maintenance period (month 4 to 24)

- Gal at stable dose (at least 16 mg/day) as achieved on day 84^c
- Matching placebo
- End-of-study/early withdrawal (month 24)

Posttreatment/follow-up (+1 month [month 25])



Notes: ^aUptitration (from 16 mg/day to 24 mg/day) or downtitration (from 24 mg/day to 16 mg/day) of dose was allowed, based on tolerability and the investigator’s judgment. Patients unable to tolerate a minimum of 16 mg/day dose were to discontinue treatment and were followed until the end of the maintenance and posttreatment period. The total number of patients included in the safety analysis set was n=2,045; ^bearly study termination, per Data Safety Monitoring Board recommendation, when the prespecified number of deaths was ascertained and a significant imbalance favoring galantamine was observed; ^ca one-time dose titration to 16 or 24 mg/day was allowed, based on the investigator’s judgment and patient tolerability.

Abbreviation: Gal, galantamine.

Neuropsychiatric Disease and Treatment downloaded from https://www.dovepress.com/ For personal use only.

Publish your work in this journal

Neuropsychiatric Disease and Treatment is an international, peer-reviewed journal of clinical therapeutics and pharmacology focusing on concise rapid reporting of clinical or pre-clinical studies on a range of neuropsychiatric and neurological disorders. This journal is indexed on PubMed Central, the ‘PscINFO’ database and CAS,

and is the official journal of The International Neuropsychiatric Association (INA). The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journal>

